VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

Data highlighted in oral presentation at World Vaccine Congress 2024 on April 3, 2024



Early data from patients eligible for evaluation at week 12 show two observations of stable disease,...

Related Keywords

United States ,Canada ,Massachusetts ,Ottawa ,Ontario ,Cambridge ,Cambridgeshire ,United Kingdom ,Rehovot ,Hamerkaz ,Israel ,Washington ,Canadian ,Brii Biosciences ,Davide Anderson ,Prehevbrio Prehevbri ,Company Quarterly Reports On Form ,Nasdaq ,Drug Administration ,Oncology Center ,Vaccines Inc ,World Vaccine Congress Washington ,Scientific Officer ,Fast Track Designation ,Orphan Drug Designation ,Data Highlights ,Study Arm ,Granulocyte Macrophage Colony Stimulating Factor ,Patient Enrollment ,Study Data Highlights ,Study Design ,Track Designation ,Accelerated Approval ,Priority Review ,Drug Evaluation ,Biologics Evaluation ,Clinical Trial Endpoints ,Cancer Drugs ,Private Securities Litigation Reform Act ,Nasdaq Capital Market ,Annual Report ,Quarterly Reports ,Markets ,